887703-73-3

Basic information

• Product Name: 5-BENZYL 3-METHYL 1-(P-FLUOROPHENYL)-4-ISOPROPYL-1H-PYRAZOLE-3,5-DICARBOXYLATE
• Synonyms: 5-BENZYL 3-METHYL 1-(P-FLUOROPHENYL)-4-ISOPROPYL-1H-PYRAZOLE-3,5-DICARBOXYLATE
• CAS NO: 887703-73-3
• Molecular Formula: C₂₂H₂₁FN₂O₄
• Molecular Weight: 396.41
• Mol File: 887703-73-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-BENZYL 3-METHYL 1-(P-FLUOROPHENYL)-4-ISOPROPYL-1H-PYRAZOLE-3,5-DICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BENZYL 3-METHYL 1-(P-FLUOROPHENYL)-4-ISOPROPYL-1H-PYRAZOLE-3,5-DICARBOXYLATE(887703-73-3)
• EPA Substance Registry System: 5-BENZYL 3-METHYL 1-(P-FLUOROPHENYL)-4-ISOPROPYL-1H-PYRAZOLE-3,5-DICARBOXYLATE(887703-73-3)

Safety Data

• Hazardous Substances Data: 887703-73-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Benzyl 3-methyl 1-(p-fluorophenyl)-4-isopropyl-1H-pyrazole-3,5-dicarboxylate is used as a potential drug candidate for its possible therapeutic applications. 5-BENZYL 3-METHYL 1-(P-FLUOROPHENYL)-4-ISOPROPYL-1H-PYRAZOLE-3,5-DICARBOXYLATE's unique structure, including the pyrazole ring and various substituents, suggests it may have specific binding affinities or interactions with biological targets, making it a valuable lead in the development of new medications.
Used in Drug Discovery:
In the field of drug discovery, 5-Benzyl 3-methyl 1-(p-fluorophenyl)-4-isopropyl-1H-pyrazole-3,5-dicarboxylate serves as a lead compound. Its chemical properties and structural features make it a promising starting point for the design and synthesis of new drugs. Further research and development are required to explore its potential in treating various conditions or diseases.

Upstream product

• 887703-72-2 1-(4-fluoro-phenyl)-4-isopropyl-4,5-dihydro-1H-pyrazole-3,5-dicarboxylic acid 5-benzyl ester 3-methyl ester 

Downstream Products

• 887703-74-4 1-(4-fluorophenyl)-4-isopropyl-1H-pyrazole-3,5-dicarboxylic acid 3-methyl ester 

Relevant articles and documents

Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: Discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl- benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia

In light of accumulating evidence that aggressive LDL-lowering therapy may offer increased protection against coronary heart disease, we undertook the design and synthesis of a novel series of HMG-CoA reductase inhibitors based upon a substituted pyrazole template. Optimizing this series using both structure-based design and molecular property considerations afforded a class of highly efficacious and hepatoselective inhibitors resulting in the identification of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzyl- carbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxy-heptanoic (PF-3052334) as a candidate for the treatment of hypercholesterolemia.

Novel pyrazole-based HMG CoA reductase inhibitors

Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.